Get the Stockscreener App
9.82
0.20%
-0.02
After Hours:
9.82
Eyepoint Pharmaceuticals Inc stock is traded at $9.82, with a volume of 478.78K.
It is down -0.20% in the last 24 hours and up +4.36% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$9.84
Open:
$9.84
24h Volume:
478.78K
Relative Volume:
0.63
Market Cap:
$675.73M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-5.3956
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
-6.39%
1M Performance:
+4.36%
6M Performance:
+28.37%
1Y Performance:
-0.61%
1-Day Range:
$9.77
$10.18
1-Week Range:
$9.77
$10.57
52-Week Range:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
9.82 | 677.11M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD - MSN
EyePoint Completes Enrollment for Phase 3 Trials - MSN
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire Inc.
Why EyePoint Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Accuracy Alerts for ROI Traders Detected - metal.it
EyePoint (EYPT) Completes Enrollment in Key LUCIA Study Ahead of Schedule - GuruFocus
How EyePoint Pharmaceuticals Inc. stock reacts to Fed policy changesWeekly Top Gainers Forecast Watchlist Released - beatles.ru
How did EYPT's revenue streams evolve in Q4 2024? - AInvest
EyePoint (EYPT) Wraps Up Enrollment for Key Phase 3 Trials in Wet AMD Treatment - GuruFocus
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration | EYPT Stock News - GuruFocus
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - EyePoint Pharmaceuticals
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025Retirement Planning Entry Points For Every Investor - jammulinksnews.com
Why is EyePoint Pharmaceuticals Inc. stock attracting strong analyst attentionCapitalize on market trends early - jammulinksnews.com
Is it the right time to buy EyePoint Pharmaceuticals Inc. stockMaximize gains with data-driven stock picks - jammulinksnews.com
Is EyePoint Pharmaceuticals Inc. a growth stock or a value stockFree Consultation - jammulinksnews.com
What catalysts could drive EyePoint Pharmaceuticals Inc. stock higher in 2025Financial News Watchlist For 2025 - jammulinksnews.com
How many analysts rate EyePoint Pharmaceuticals Inc. as a “Buy”Capitalize on proven trading setups - jammulinksnews.com
Does EyePoint Pharmaceuticals Inc. stock perform well during market downturnsBuild your wealth with consistent stock growth - jammulinksnews.com
How EyePoint Pharmaceuticals Inc. stock performs during market volatilityWatchlist Winner Update - metal.it
EyePoint Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowSafer Investing With Bigger Upside - metal.it
What makes EyePoint Pharmaceuticals Inc. stock price move sharplyFree Expert-Led Investment Training - metal.it
How high can EyePoint Pharmaceuticals Inc. stock price go in 2025Market-leading growth rates - jammulinksnews.com
What institutions are buying EyePoint Pharmaceuticals Inc. stock nowFree Stock Market Trend Analysis - jammulinksnews.com
Is EyePoint Pharmaceuticals Inc. a good long term investmentStrong return on assets - Autocar Professional
What analysts say about EyePoint Pharmaceuticals Inc. stockExceptional profit margins - Autocar Professional
EyePoint Pharmaceuticals Inc. Stock Analysis and ForecastExceptional portfolio growth - Autocar Professional
What drives EyePoint Pharmaceuticals Inc. stock priceGame-changing returns - jammulinksnews.com
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):